On the other hand, studies that examined patients who received short-duration DAPT that included aspirin and a P2Y12 inhibitor followed by only a P2Y12 inhibitor did not find any differences between short- and standard-duration DAPT regarding efficacy outcomes (all-cause death, major adverse cardiovascular events (MACE), myocardial infarction, stroke, and ST), but did find that major bleeding events were significantly reduced with short-duration DAPT. The gene discussed is P2RY12; the disease is myocardial infarction.